Evolus EOLS
NASDAQ EOLS
$6.83 -0.15 (-2.15%)
As of: Nov 10, 2026 · 3:50 PM EST

Evolus (EOLS) Convertible Debt (2020)

Updated

Evolus' Convertible Debt came in at $40.51 million for Q4 2020, up 0.8% from the prior quarter.

Analysis

Evolus (EOLS) Convertible Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Evolus 455.33 Mn 264.84 Mn 50.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 40.51 Mn
Sep 30, 2020 40.20 Mn
API Access

Evolus Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=EOLS&period=max&api_key=YOUR_API_KEY